The priority review for Dupixent is for the treatment of adult patients whose CRSwNP is inadequately controlled. CRSwNP is a chronic disease of the upper airway. It is
The post Sanofi’s Dupixent secures FDA priority review for CRSwNP appeared first on Pharmaceutical Business review.
Original Article: Sanofi’s Dupixent secures FDA priority review for CRSwNP